We provide you with 20 years of free, institutional-grade data for XCUR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of XCUR. Explore the full financial landscape of XCUR stock.
| Reported Date | CIK | Ticker | Type |
|---|
Exicure(NASDAQ:XCUR) 
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clini...
Website: http://www.exicuretx.com
Founded: 2011
CEO: David Giljohann
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about XCUR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.